Caredx announces repurchase of 5% of outstanding shares

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna), – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. the share repurchase follows the completion of the company's seven.
CDNA Ratings Summary
CDNA Quant Ranking